Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hypofractionated external beam · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| hypofractionated external beam | PROCEDURE | - |
Inclusion Criteria: * patients with histologically or cytologically proven newly diagnosed small cell lung cancer * confirmation from the treating radiation oncologist that the patient has limited stage disease (i.e. disease that can be encompassed by radiotherapy portals without exposing patient t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Hypofractionated external beam is used for lung neoplasms, specifically small cell carcinoma of the lung. It is a form of radiotherapy delivered in a hypofractionated regimen, meaning larger doses per fraction over fewer sessions, for the treatment of this type of lung cancer.
Hypofractionated external beam is being developed by Avalon GloboCare Corp. (NASDAQ: ALBT). The company is conducting clinical research on this radiotherapy approach for lung cancer.
Hypofractionated external beam is in Phase 1 clinical development. It is an investigational radiotherapy regimen, not yet approved by regulatory authorities, and is being studied for safety and dosing in patients with small cell lung cancer.
Hypofractionated external beam has one completed Phase 1 trial, NCT00469222, titled 'Hypofractionated Radiotherapy for Small Cell Lung Cancer.' This trial enrolled 24 participants in Canada and evaluated the regimen in patients with lung neoplasm and small cell carcinoma.
Hypofractionated external beam is a specific radiotherapy approach that uses larger doses per treatment session compared to conventional fractionation. It is being studied as a treatment for small cell lung cancer, but it is not the same as standard radiotherapy regimens.